Published in J Neurol Neurosurg Psychiatry on June 09, 2016
Narrative Organization Deficit in Lewy Body Disorders Is Related to Alzheimer Pathology. Front Neurosci (2017) 0.75
Decision-Making Deficits Associated with Amyloidosis in Lewy Body Disorders. Front Hum Neurosci (2017) 0.75
White matter hyperintensities are more highly associated with preclinical Alzheimer's disease than imaging and cognitive markers of neurodegeneration. Alzheimers Dement (Amst) (2016) 0.75
Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. Mov Disord (2017) 0.75
Mild cognitive impairment in Parkinson's disease: a distinct clinical entity? Transl Neurodegener (2017) 0.75
Neural Correlates of Verbal Episodic Memory and Lexical Retrieval in Logopenic Variant Primary Progressive Aphasia. Front Neurosci (2017) 0.75
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet (2011) 9.10
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (2010) 6.17
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
N4ITK: improved N3 bias correction. IEEE Trans Med Imaging (2010) 5.05
Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med (2012) 3.98
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Visuospatial judgment. A clinical test. Arch Neurol (1978) 3.37
CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology (2010) 2.67
Construct and concurrent validity of the Hopkins Verbal Learning Test-revised. Clin Neuropsychol (1999) 2.65
The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol (2011) 2.65
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.40
Evaluation of volume-based and surface-based brain image registration methods. Neuroimage (2010) 2.38
Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology (2014) 2.15
Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci (2010) 2.12
Neuropathologic substrates of Parkinson disease dementia. Ann Neurol (2012) 2.10
Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain (2011) 2.02
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol (2013) 1.83
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci (2013) 1.82
An open source multivariate framework for n-tissue segmentation with evaluation on public data. Neuroinformatics (2011) 1.74
Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm (Vienna) (2004) 1.74
101 labeled brain images and a consistent human cortical labeling protocol. Front Neurosci (2012) 1.66
Large-scale evaluation of ANTs and FreeSurfer cortical thickness measurements. Neuroimage (2014) 1.59
CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry (2010) 1.55
Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord (2009) 1.54
Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging (2004) 1.44
Parkinsonianlike signs and risk of incident Alzheimer disease in older persons. Arch Neurol (2003) 1.43
APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol (2013) 1.41
Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci Lett (2012) 1.19
Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease. Drugs Aging (2000) 1.09
Validity of modulation and optimal settings for advanced voxel-based morphometry. Neuroimage (2013) 1.07
Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology (2012) 1.04
Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease. Neurobiol Aging (2014) 0.88
Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. Mov Disord (2015) 0.87
Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity. Acta Neuropathol Commun (2015) 0.84
Evaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases. J Neuropathol Exp Neurol (2017) 0.76
Structural Correlation-based Outlier Rejection (SCORE) algorithm for arterial spin labeling time series. J Magn Reson Imaging (2016) 0.75
Deep Generative Medical Image Harmonization for Improving Cross-Site Generalization in Deep Learning Predictors. J Magn Reson Imaging (2021) 0.75